Replies to post #12022 on FDA Plays

[ToysInTheAttic]

IMUC ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference
8:00 am ET 02/11/2011- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Feb. 11, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.

A webcast of the presentation will be available one hour after the presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm and will be accessible until May 16, 2011.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.